Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
12 2023
Historique:
revised: 06 09 2023
received: 03 07 2023
accepted: 19 09 2023
medline: 16 11 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: ppublish

Résumé

Low-count monoclonal B-cell lymphocytosis (MBL

Identifiants

pubmed: 37792579
doi: 10.1002/ajh.27119
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1909-1922

Informations de copyright

© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325-332.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.
Rawstron AC, Bennett FL, O'Connor SJM, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(19):575-583.
Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009;114(2):33-37.
Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100(2):635-639.
Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5− B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004;103(6):2337-2342.
Slager SL, Parikh SA, Achenbach SJ, et al. Progression and survival of MBL: a screening study of 10 139 individuals. Blood. 2022;140(15):1702-1709.
Criado I, Rodríguez-Caballero A, Gutiérrez ML, et al. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica. 2018;103(7):1198-1208.
Shanafelt TD, Kay NE, Parikh SA, et al. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia. 2021;35(1):239-244.
Criado I, Blanco E, Rodríguez-Caballero A, et al. Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia. 2018;32(12):2701-2705.
Criado I, Nieto WG, Oliva-Ariza G, et al. Age- and sex-matched Normal leukocyte subset ranges in the general population defined with the EuroFlow lymphocyte screening tube (LST) for monoclonal B-cell lymphocytosis (MBL) vs. Non-MBL subjects. Cancers (Basel). 2022;15(1):58.
Hauswirth AW, Almeida J, Nieto WG, et al. Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets. Am J Hematol. 2012;87(7):721-724.
Whitaker JA, Parikh SA, Shanafelt TD, et al. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021;39(7):1122-1130.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA J Am Med Assoc. 2020;323(13):1239-1242.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Oliva-Ariza G, Fuentes-Herrero B, Carbonell C, et al. High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients. Blood. 2023;141(3):309-314.
Chen R, Sang L, Jiang M, Yang Z, Jia N. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146(1):89-100.
Rodriguez L, Pekkarinen PT, Lakshmikanth T, et al. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Rep Med. 2020;1(5):100078.
Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 80-. 2020;369(6508).
Carsetti R, Zaffina S, Piano Mortari E, et al. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol. 2020;11(December):1-16.
Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103.
Flores-Montero J, Grigore G, Fluxá R, et al. EuroFlow lymphoid screening tube (LST) data base for automated identification of blood lymphocyte subsets. J Immunol Methods. 2019;475:112662.
Blanco E, Pérez-Andrés M, Arriba-Méndez S, et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018;141(6):2208-2219.e16.
van der Pan K, de Bruin-Versteeg S, Damasceno D, et al. Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood. Front Immunol. 2022;13(September):1-26.
Hultin LE, Chow M, Jamieson BD, et al. Comparison of interlaboratory variation in absolute T-cell counts by single-platform and optimized dual-platform methods. Cytom Part B Clin Cytom. 2010;78(3):194-200.
Leuzinger K, Osthoff M, Dräger S, et al. Comparing immunoassays for sars-cov-2 antibody detection in patients with and without laboratory-confirmed sars-cov-2 infection. J Clin Microbiol. 2021;59(12):1-14.
Al-Jighefee HT, Yassine HM, Nasrallah GK. Evaluation of antibody response in symptomatic and asymptomatic covid-19 patients and diagnostic assessment of new IgM/IgG elisa kits. Pathogens. 2021;10(2):1-18.
Nguyen NN, Mutnal MB, Gomez RR, et al. Correlation of ELISA method with three other automated serological tests for the detection of anti-SARS-CoV-2 antibodies. PLoS One. 2020;15(10 October):1-9.
Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257-1275.e8.
Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):1-21.
Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024-1042.e21.
Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12(1):1-7.
Zhou R, To KKW, Wong YC, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864-877.e5.
Shen Y, Freeman JA, Holland J, et al. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br J Haematol. 2022;197(1):41-51.
Shen Y, Freeman JA, Holland J, et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood. 2022;140(25):2709-2721.
To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574.
Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-442.
Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021;12(1):1-14.

Auteurs

Guillermo Oliva-Ariza (G)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Blanca Fuentes-Herrero (B)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Quentin Lecrevisse (Q)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Cristina Carbonell (C)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.

Alba Pérez-Pons (A)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Alba Torres-Valle (A)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Julio Pozo (J)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

José Ángel Martín-Oterino (JÁ)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.

Óscar González-López (Ó)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Amparo López-Bernús (A)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.
Department of Infectious Diseases, University Hospital of Salamanca, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.

Marta Bernal-Ribes (M)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.

Moncef Belhassen-García (M)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.
Department of Infectious Diseases, University Hospital of Salamanca, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Salamanca, Spain.

Oihane Pérez-Escurza (O)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Martín Pérez-Andrés (M)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Lourdes Vazquez (L)

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.

Guillermo Hernández-Pérez (G)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.

Francisco Javier García Palomo (FJ)

Spanish National DNA Bank Carlos III, NUCLEUS, University of Salamanca, Salamanca, Spain.

Pilar Leoz (P)

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.

Pilar Costa-Alba (P)

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Emergency Department, University Hospital of Salamanca, Salamanca, Spain.

Elena Pérez-Losada (E)

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Intensive Care Department, University Hospital of Salamanca, Salamanca, Spain.

Ana Yeguas (A)

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.

Miryam Santos Sánchez (M)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Marta García-Blázquez (M)

Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.

F Javier Morán-Plata (FJ)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Daniela Damasceno (D)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Vitor Botafogo (V)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Noemí Muñoz-García (N)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

Rafael Fluxa (R)

Cytognos SL, Salamanca, Spain.

Jacques J M van Dongen (JJM)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.

Miguel Marcos (M)

Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Department of Internal Medicine, University Hospital of Salamanca, Salamanca, Spain.

Julia Almeida (J)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Alberto Orfao (A)

Translational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC - University of Salamanca); Cytometry Service, NUCLEUS, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH